Jorge D. Gallo

1.0k total citations
23 papers, 558 citations indexed

About

Jorge D. Gallo is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jorge D. Gallo has authored 23 papers receiving a total of 558 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 10 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jorge D. Gallo's work include PI3K/AKT/mTOR signaling in cancer (5 papers), Cancer Treatment and Pharmacology (4 papers) and Advanced Breast Cancer Therapies (3 papers). Jorge D. Gallo is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (5 papers), Cancer Treatment and Pharmacology (4 papers) and Advanced Breast Cancer Therapies (3 papers). Jorge D. Gallo collaborates with scholars based in United States, Switzerland and Italy. Jorge D. Gallo's co-authors include Diane Wang, Antonello Abbattista, R. Dewji, Lucy Scott, Evan A. Mulligan, Hilary Calvert, Richard H. Wilson, Neil Steven, Ruth Plummer and Paul Lorigan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Jorge D. Gallo

23 papers receiving 548 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jorge D. Gallo United States	10	355	337	127	75	56	23	558
Andrea Ghelli Luserna di Rorà Italy	13	513 1.4×	303 0.9×	64 0.5×	98 1.3×	63 1.1×	38	735
Sang-Hyun Song South Korea	14	512 1.4×	215 0.6×	97 0.8×	125 1.7×	26 0.5×	18	644
Zahra Asgari United States	9	207 0.6×	316 0.9×	113 0.9×	126 1.7×	42 0.8×	16	537
Florian Bellutti Austria	7	281 0.8×	196 0.6×	163 1.3×	99 1.3×	86 1.5×	13	538
Giulia Scotto Italy	10	177 0.5×	242 0.7×	106 0.8×	99 1.3×	21 0.4×	19	458
Lorenzo Castagnoli Italy	17	368 1.0×	406 1.2×	105 0.8×	169 2.3×	26 0.5×	31	726
Aparajitha Vaidyanathan United Kingdom	5	246 0.7×	282 0.8×	50 0.4×	59 0.8×	23 0.4×	7	406
Jared S. Hierman United States	2	255 0.7×	314 0.9×	73 0.6×	108 1.4×	24 0.4×	2	499
Gregory C. Stachelek United States	7	225 0.6×	191 0.6×	72 0.6×	142 1.9×	29 0.5×	15	414
Hoa Q. Trummell United States	13	305 0.9×	360 1.1×	176 1.4×	94 1.3×	18 0.3×	19	620

Countries citing papers authored by Jorge D. Gallo

Since Specialization

Citations

This map shows the geographic impact of Jorge D. Gallo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jorge D. Gallo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jorge D. Gallo more than expected).

Fields of papers citing papers by Jorge D. Gallo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jorge D. Gallo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jorge D. Gallo. The network helps show where Jorge D. Gallo may publish in the future.

Co-authorship network of co-authors of Jorge D. Gallo

This figure shows the co-authorship network connecting the top 25 collaborators of Jorge D. Gallo. A scholar is included among the top collaborators of Jorge D. Gallo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jorge D. Gallo. Jorge D. Gallo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sutaria, Dhruvitkumar S., Adam Harris, Ryan Johnson, et al.. (2022). Drug–Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer. Pharmaceutics. 14(10). 2101–2101. 7 indexed citations

Sutaria, Dhruvitkumar S., Priya Agarwal, Dale Miles, et al.. (2022). Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications. Clinical and Translational Science. 15(12). 2989–2999. 3 indexed citations

Pook, David, Daniel M. Geynisman, Joan Carles, et al.. (2022). A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib + rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 40(6_suppl). 95–95. 5 indexed citations

Gallo, Jorge D., et al.. (2019). Performance of different ADRC based control methods in a nonlinear plant with uncertainties. 1–6. 1 indexed citations

Bendell, J. C., Christopher H. Lieu, Kanwal Raghav, et al.. (2019). A phase Ib study of the safety and efficacy of atezolizumab (atezo) + bevacizumab (bev) + cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC). Annals of Oncology. 30. v227–v228. 3 indexed citations

Noguchi, Shinzaburo, Nobuo Shinohara, Tetsuhide Ito, et al.. (2017). Relationship between Pulmonary Adverse Events and Everolimus Exposure in Japanese and Non-Japanese Patients: A Meta-Analysis of Oncology Trials. Oncology. 92(5). 243–254. 5 indexed citations

Rugo, Hope S., G. N. Hortobágyi, James C. Yao, et al.. (2016). Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. Annals of Oncology. 27(3). 519–525. 62 indexed citations

Larkin, James, Grant A. McArthur, Antoni Ribas, et al.. (2016). Clinical predictors of response for coBRIM: A phase III study of cobimetinib (C) in combination with vemurafenib (V) in advanced BRAF-mutated melanoma (MM).. Journal of Clinical Oncology. 34(15_suppl). 9528–9528. 2 indexed citations

Shapiro, Geoffrey I., Katherine M. Bell‐McGuinn, Julian R. Molina, et al.. (2015). First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. Clinical Cancer Research. 21(8). 1888–1895. 97 indexed citations

10.

Brannon, A. Rose, Melissa Frizziero, David Chen, et al.. (2015). Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus. Molecular Case Studies. 2(2). a000620–a000620. 6 indexed citations

11.

Cheung, Wing K., et al.. (2015). Bioavailability of everolimus administered as a single 5 mg tablet versus five 1 mg tablets: a randomized, open-label, two-way crossover study of healthy volunteers. Clinical Pharmacology Advances and Applications. 7. 11–11. 9 indexed citations

12.

Rugo, Hope S., James C. Yao, Marianne Pavel, et al.. (2014). Stomatitis incidence and its relationship with efficacy: A meta-analysis of everolimus clinical studies.. Journal of Clinical Oncology. 32(26_suppl). 151–151. 1 indexed citations

13.

Rugo, Hope S., James C. Yao, Gabriel N. Hortobágyi, et al.. (2014). Meta-analysis of stomatitis incidence in everolimus (EVE) clinical studies and its relationship with efficacy.. Journal of Clinical Oncology. 32(15_suppl). 645–645. 4 indexed citations

14.

Plummer, Ruth, Paul Lorigan, Neil Steven, et al.. (2013). A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemotherapy and Pharmacology. 71(5). 1191–1199. 143 indexed citations

15.

Qiu, Ming, Qinghai Peng, Christopher L. Carroll, et al.. (2012). Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells. Cancer Letters. 328(2). 261–270. 109 indexed citations

16.

Britten, Carolyn D., Zev A. Wainberg, Josep Tabernero, et al.. (2012). 358 A Multi-arm Phase 1 Dose Escalation Study of Safety, Pharmacokinetics, and Pharmacodynamics of the Dual PI3K/mTOR Inhibitors PF-04691502 (oral) and PF-05212384 (IV) in Combination with the MEK Inhibitor PD-0325901 or Irinotecan in Patients with Advanced Cancer. European Journal of Cancer. 48. 109–109. 10 indexed citations

17.

Rosen, Lee S., Todd A. Blumenkopf, Aurora Breazna, et al.. (2011). Abstract A177: Phase 1, dose-escalation, safety, pharmacokinetic and pharmacodynamic study of single agent PF-03758309, an oral PAK inhibitor, in patients with advanced solid tumors.. Molecular Cancer Therapeutics. 10(11_Supplement). A177–A177. 10 indexed citations

18.

Brega, Nicoletta, Grant A. McArthur, Cedrik M. Britten, et al.. (2010). Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase.. Journal of Clinical Oncology. 28(15_suppl). 3062–3062. 17 indexed citations

19.

DiPaola, Robert S., Robert E. Weiss, Kenneth B. Cummings, et al.. (1997). Effect of 13-cis-retinoic acid and alpha-interferon on transforming growth factor beta1 in patients with rising prostate-specific antigen.. PubMed. 3(11). 1999–2004. 18 indexed citations

20.

Hudes, G. R., Coleman K. Obasaju, Angela Chapman, et al.. (1995). Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer.. PubMed. 22(3 Suppl 6). 6–11. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact